Sanofi to take 26.4% stake in Cheplapharm

On 14 September 2026, Sanofi announced its intention to form a strategic partnership with German pharmaceutical company Cheplapharm. Under the agreement, Cheplapharm will take over 20 mature medicines and three global manufacturing sites from Sanofi. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, expanding a collaboration that began in 2014.

The divested portfolio includes the anticoagulant Lovenox/Clexane (enoxaparin), excluding the United States market. The transaction also includes the transfer of three manufacturing facilities: Csanyikvölgy in Hungary with approximately 400 employees, Jurong in Singapore with approximately 100 employees, and Ploërmel in France with approximately 65 employees. Existing employment arrangements and collective agreements will be maintained.

The commercial transfer of the medicines is scheduled to start in the first quarter of 2027, with the handover of the manufacturing sites to follow. Subject to employee consultations, regulatory clearances, and closing conditions, the transaction is expected to close by the third quarter of 2027. Sanofi confirmed the transaction will have no impact on its financial guidance for 2026.